• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测长方案组新鲜周期中重度卵巢过度刺激综合征风险的列线图模型。

Nomogram model to predict the risk of moderate to severe ovarian hyperstimulation syndrome of long protocol group in fresh cycle.

作者信息

Deng Huihui, Dou Qian, Guo Peipei, Liu Huanxin, Xiang Yungai, Geng Xujing, Li Pengfen, Zhang Dan

机构信息

The Reproductive Medicine Department of the Second Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.

出版信息

Sci Rep. 2025 Mar 17;15(1):9211. doi: 10.1038/s41598-025-94049-3.

DOI:10.1038/s41598-025-94049-3
PMID:40097634
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11914069/
Abstract

To explore the risk factors of moderate to severe ovarian hyperstimulation syndrome (Ovarian hyperstimulation syndrome, OHSS) in patients using the early-follicular phase long-acting gonadotropin-releasing hormone agonist long protocol (EFLL) group in fresh cycles, and to establish a nomogram model to predict the risk of moderate to severe OHSS. We retrospectively analyzed clinical data from 4,204 patients who receiving in vitro fertilization/intracytoplasmic sperm injection and embryo transfer (IVF/ICSI-ET) at the Reproductive Medicine Department of the Second Affiliated Hospital of Zhengzhou University from January 2015 to August 2024. A total of 4204 cases using EFLL protocol were included. The clinical cases were randomly divided into a modeling group (2,942 cases) and a verification group (1,262 cases) at a ratio of 7:3. Logistic regression analysis was used to identify the independent risk factors associated with the occurrence of moderate to severe OHSS in fresh cycles, Based on the selected independent risk factors and correlated regression coefficients, we established a nomogram model to predict the probability of moderate to severe OHSS in this patients, and the predictive accuracy of the model was measured using the area under the receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis. Univariate and multivariate logistic regression analyses showed that Antal follicle count (AFC) (OR, 1.04; 95%CI, 1.02-1.07; P = 0.002), estrogen levels on the day of hCG injection (OR, 1.01; 95%CI, 1.01-1.01; P<0.01), progesterone levels on the day of hCG injection (OR, 1.18; 95%CI, 1.04-1.34; P = 0.011),, whether the patient had a hypothyroidism (OR, 3.62; 95%CI, 2.10-6.23; P < 0.001), and infertility type (OR, 0.59; 95%CI, 0.35-0.99; P = 0.048) are the independent risk factors for the occurrence of moderate to severe OHSS in fresh cycles. The ROC curve (AUC) being 0.83 (95% CI: 0.78-0.88) for the modeling group and 0.84 (95% CI: 0.78-0.90) for the validation group. The calibration curve and decision curve demonstrated good consistency between the predicted rates of moderate to severe OHSS and the actual incidence. AFC, estrogen levels on the day of hCG injection, progesterone levels on the day of hCG injection, whether the patient had a hypothyroidism, and infertility type are the independent risk factors for moderate to moderate to severe OHSS in fresh cycles. The established nomogram model has proven to be a novel tool that can intuitively predict the incidence of moderate to severe OHSS in the patients that receiving EFLL protocol in fresh cycles, and this nomogram model developed in this study showed better net benefit, have a good clinical applicability for decision-making and could help the clinician to set up a better clinical management strategies for conducting a precise personal therapy.

摘要

为探讨在新鲜周期中使用卵泡早期长效促性腺激素释放激素激动剂长方案(EFLL)的患者发生中重度卵巢过度刺激综合征(OHSS)的危险因素,并建立列线图模型以预测中重度OHSS的风险。我们回顾性分析了2015年1月至2024年8月在郑州大学第二附属医院生殖医学科接受体外受精/卵胞浆内单精子注射及胚胎移植(IVF/ICSI-ET)的4204例患者的临床资料。共纳入4204例使用EFLL方案的病例。将临床病例按7:3的比例随机分为建模组(2942例)和验证组(1262例)。采用Logistic回归分析确定与新鲜周期中重度OHSS发生相关的独立危险因素,基于所选独立危险因素及相关回归系数,建立列线图模型以预测该类患者中重度OHSS的概率,并采用受试者操作特征(ROC)曲线下面积、校准曲线和决策曲线分析来评估模型的预测准确性。单因素和多因素Logistic回归分析显示,基础卵泡数(AFC)(OR,1.04;95%CI,1.02-1.07;P = 0.002)、人绒毛膜促性腺激素(hCG)注射日雌激素水平(OR,1.01;95%CI,1.01-1.01;P<0.01)、hCG注射日孕激素水平(OR,1.18;95%CI,1.04-1.34;P = 0.011)、患者是否患有甲状腺功能减退症(OR,3.62;95%CI,2.10-6.23;P < 0.001)以及不孕类型(OR,0.59;95%CI,0.35-0.99;P =  0.048)是新鲜周期中重度OHSS发生的独立危险因素。建模组的ROC曲线(AUC)为0.83(95%CI:0.78-0.88),验证组为0.84(95%CI:0.78-0.90)。校准曲线和决策曲线显示中重度OHSS预测率与实际发生率之间具有良好的一致性。AFC、hCG注射日雌激素水平、hCG注射日孕激素水平、患者是否患有甲状腺功能减退症以及不孕类型是新鲜周期中重度OHSS的独立危险因素。所建立的列线图模型已被证明是一种新颖的工具,可直观地预测新鲜周期中接受EFLL方案患者中重度OHSS的发生率,且本研究开发的该列线图模型显示出更好的净效益,具有良好的临床决策适用性,有助于临床医生制定更好的临床管理策略以进行精准的个体化治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20d5/11914069/a233d7e066f4/41598_2025_94049_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20d5/11914069/aac76a9e986b/41598_2025_94049_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20d5/11914069/ee9a68d71aa8/41598_2025_94049_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20d5/11914069/a233d7e066f4/41598_2025_94049_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20d5/11914069/aac76a9e986b/41598_2025_94049_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20d5/11914069/ee9a68d71aa8/41598_2025_94049_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20d5/11914069/a233d7e066f4/41598_2025_94049_Fig3_HTML.jpg

相似文献

1
Nomogram model to predict the risk of moderate to severe ovarian hyperstimulation syndrome of long protocol group in fresh cycle.预测长方案组新鲜周期中重度卵巢过度刺激综合征风险的列线图模型。
Sci Rep. 2025 Mar 17;15(1):9211. doi: 10.1038/s41598-025-94049-3.
2
Nomogram Model to Predict the Probability of Ovarian Hyperstimulation Syndrome in the Treatment of Patients With Polycystic Ovary Syndrome.预测多囊卵巢综合征患者卵巢过度刺激综合征发生概率的列线图模型。
Front Endocrinol (Lausanne). 2021 Aug 6;12:619059. doi: 10.3389/fendo.2021.619059. eCollection 2021.
3
Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.在拮抗剂辅助生殖技术中,促性腺激素释放激素激动剂与绒毛膜促性腺激素用于卵母细胞触发的比较
Cochrane Database Syst Rev. 2014 Oct 31;2014(10):CD008046. doi: 10.1002/14651858.CD008046.pub4.
4
Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.促性腺激素释放激素(GnRH)拮抗剂方案与GnRH激动剂方案中严重卵巢过度刺激综合征的风险:一项纳入1050个首次体外受精/卵胞浆内单精子注射周期的随机对照试验
Hum Reprod. 2016 Jun;31(6):1253-64. doi: 10.1093/humrep/dew051. Epub 2016 Apr 8.
5
Constructing a predictive model for live birth following fresh embryo transfer in antagonist protocol for polycystic ovary syndrome.构建拮抗剂方案新鲜胚胎移植后多囊卵巢综合征患者活产预测模型。
J Assist Reprod Genet. 2024 Oct;41(10):2709-2719. doi: 10.1007/s10815-024-03232-4. Epub 2024 Aug 21.
6
Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.促性腺激素释放激素激动剂扳机后改良黄体支持在高风险患者中可获得一致的高临床妊娠率和低卵巢过度刺激综合征率:一项回顾性多中心研究。
Hum Reprod. 2013 Sep;28(9):2529-36. doi: 10.1093/humrep/det304. Epub 2013 Jul 19.
7
[Efficacy analysis of letrozole combined with gonadotropin-releasing hormone antagonists in patients with high risk of ovarian hyperstimulation syndrome undergoing total embryo freezing].来曲唑联合促性腺激素释放激素拮抗剂在接受全胚冷冻的卵巢过度刺激综合征高危患者中的疗效分析
Zhonghua Yi Xue Za Zhi. 2024 Aug 6;104(30):2823-2829. doi: 10.3760/cma.j.cn112137-20240107-00044.
8
Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.在拮抗剂辅助生殖技术周期中,促性腺激素释放激素激动剂与绒毛膜促性腺激素用于触发卵母细胞的比较。
Cochrane Database Syst Rev. 2011 Jan 19(1):CD008046. doi: 10.1002/14651858.CD008046.pub3.
9
GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.促性腺激素释放激素激动剂与绒毛膜促性腺激素触发在不同患者的体外受精/卵胞浆内单精子注射周期中的应用:一项回顾性研究。
J Obstet Gynaecol. 2020 Aug;40(6):837-842. doi: 10.1080/01443615.2019.1674262. Epub 2019 Dec 3.
10
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).针对接受体外受精加卵胞浆内单精子注射(IVF/ICSI)的女性,使用卵巢储备标志物进行个性化促性腺激素剂量选择。
Cochrane Database Syst Rev. 2018 Feb 1;2(2):CD012693. doi: 10.1002/14651858.CD012693.pub2.

引用本文的文献

1
Risk prediction models for ovarian hyperstimulation syndrome: a systematic review and meta-analysis.卵巢过度刺激综合征的风险预测模型:一项系统评价与荟萃分析
BMC Pregnancy Childbirth. 2025 Aug 18;25(1):860. doi: 10.1186/s12884-025-07971-9.

本文引用的文献

1
Ovarian Hyperstimulation syndrome combined with hypothyroidism: a comprehensive review.卵巢过度刺激综合征合并甲状腺功能减退症:全面综述。
J Ovarian Res. 2024 May 9;17(1):98. doi: 10.1186/s13048-024-01406-3.
2
The Incidence of Moderate and Severe Ovarian Hyperstimulation Syndrome in Hospitalized Patients in China.中国住院患者中重度卵巢过度刺激综合征的发病率
Health Data Sci. 2023 Mar 15;3:0009. doi: 10.34133/hds.0009. eCollection 2023.
3
Thyroid function modifications in women undergoing controlled ovarian hyperstimulation for in vitro fertilization: a systematic review and meta-analysis.
接受体外受精控制性卵巢过度刺激的女性甲状腺功能的改变:系统评价和荟萃分析。
Fertil Steril. 2021 Jul;116(1):218-231. doi: 10.1016/j.fertnstert.2021.01.029. Epub 2021 Apr 7.
4
The depot GnRH agonist protocol improves the live birth rate per fresh embryo transfer cycle, but not the cumulative live birth rate in normal responders: a randomized controlled trial and molecular mechanism study.促性腺激素释放激素激动剂扳机方案可提高新鲜胚胎移植周期的活产率,但不能提高正常反应者的累积活产率:一项随机对照试验及分子机制研究。
Hum Reprod. 2020 Jun 1;35(6):1306-1318. doi: 10.1093/humrep/deaa086.
5
Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management.卵巢过度刺激综合征:关于其病理生理学、危险因素、预防、分类及管理的叙述性综述
Iran J Med Sci. 2018 May;43(3):248-260.
6
A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.一种新的卵母细胞成熟触发方法,使用 1500IU 的人绒毛膜促性腺激素加 450IU 的卵泡刺激素,可能会降低所有体外受精刺激方案中的卵巢过度刺激综合征。
J Assist Reprod Genet. 2018 Feb;35(2):297-307. doi: 10.1007/s10815-017-1074-4. Epub 2017 Oct 30.
7
Prevention and management of ovarian hyperstimulation syndrome.卵巢过度刺激综合征的预防与管理
Thromb Res. 2017 Mar;151 Suppl 1:S61-S64. doi: 10.1016/S0049-3848(17)30070-1.
8
Subclinical hypothyroidism diagnosed by thyrotropin-releasing hormone stimulation test in infertile women with basal thyroid-stimulating hormone levels of 2.5 to 5.0 mIU/L.在基础促甲状腺激素水平为2.5至5.0 mIU/L的不孕女性中,通过促甲状腺激素释放激素刺激试验诊断出的亚临床甲状腺功能减退。
Obstet Gynecol Sci. 2014 Nov;57(6):507-12. doi: 10.5468/ogs.2014.57.6.507. Epub 2014 Nov 20.
9
The development of ovarian hyperstimulation syndrome in the implementation of assisted reproductive technology in women with a background of endocrine pathology.在有内分泌病理学背景的女性实施辅助生殖技术过程中卵巢过度刺激综合征的发生情况。
Gynecol Endocrinol. 2014 Oct;30 Suppl 1:25-9. doi: 10.3109/09513590.2014.945780.
10
Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles.卵母细胞数量作为卵巢过度刺激综合征和活产预测指标的分析:256381 个体外受精周期。
Fertil Steril. 2014 Apr;101(4):967-73. doi: 10.1016/j.fertnstert.2013.12.026. Epub 2014 Jan 23.